Last summer, a trial was carried out by Eli Lilly for its Alzheimer's drug solanezumab. But the trial failed that time. However, it has been said that Lilly is again going to initiate the clinical trials.

The pharmaceutical giant was of the view that they have a number of evidences that shows that the drug works for mild disease. Therefore, they are again going to start the trials.

This time, they will be concentrating on patients having mild disease. Last time, 1,300 patients were enrolled for clinical trial. But this time they have increased the number to 2,100.

It is said that patients will only be taken if they will be having beta amyloid. Authorities concerned were of the view that last time, such thing did not happen. As last time, there was quarter of patients, who were not having signs of beta amyloid.

Eric Siemers, Senior Medical Director of Lilly's Alzheimer's Disease Team, said that they are having great hopes from this trial. It is expected that this trial will be able to differentiate between solanezumab and placebo.

Maria Carrillo, Vice President of medical and scientific relations at the Alzheimer's Association, said that they are quite happy to know the decision of Lilly.